3.520SEK+0.57%Mkt Cap: 72.69M SEKP/E: —Last update: 2026-06-01
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap72.69M SEK
Enterprise Value404.87M SEK
Revenue (TTM)287.55M SEK
Gross Profit232.43M SEK
Net Income (TTM)-159.88M SEK
Revenue/Share13.93 SEK
Last Price3.520 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees140
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)1.46
PEG—
EV/EBITDA-15.15
EV/Revenue1.41
P/S0.25
P/B0.18
EPS (TTM)-7.74
EPS (Forward)2.40
52W Range
3.3001% of range30.00
52W High30.00 SEK
52W Low3.300 SEK
Profitability
Gross Margin82.15%
Oper. Margin-158.52%
EBITDA Margin-9.29%
Profit Margin-56.51%
ROE-40.39%
ROA-17.55%
Growth
Revenue Growth-14.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-31.93M SEK
CapEx (TTM)—
FCF Margin1.13%
FCF Yield4.46%
Net Debt332.59M SEK
Net Debt/EBITDA-12.45
Balance Sheet
Debt/Equity0.87
Current Ratio1.37
Quick Ratio0.69
Book Value/Sh19.17 SEK
Cash/Share0.6580 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating0.0 (Hold)
Target (Mean)8.000 SEK
Target Range8.000 SEK – 8.000 SEK
# Analysts1
Ownership
Shares Out.20.65M
Float14.20M
Insiders27.42%
Institutions0.01%
Technical
SMA 504.464 (-21.2%)
SMA 20013.43 (-73.8%)
Beta0.51
S&P 52W Chg27.70%
Avg Vol (30d)5.15K
Avg Vol (10d)5.57K
Technical Indicators
RSI (14)26.7
MACD-0.3278
MACD Signal-0.3169
MACD Hist.-0.0109
BB Upper4.606 SEK
BB Middle4.058 SEK
BB Lower3.510 SEK
BB Width27.01%
ATR (14)0.2099 SEK
Vol Ratio (20d)0.74x